DUSP22 Rearrangement Is Associated With a Distinctive Immunophenotype but Not Outcome in Patients With Systemic Alk-Negative Anaplastic Large Cell Lymphoma

Authors

Lianqun Qiu
Guilin Tang
Shaoying Li
Francisco Vega
Pei Lin
Sa A Wang
Wei Wang
Swaminathan P Iyer
Luis Malpica
Roberto N Miranda
Sergej Konoplev
Zhenya Tang
Hong Fang
L Jeffrey Medeiros
Jie Xu

Publication Date

6-1-2023

Journal

Haematologica

Abstract

DUSP22 rearrangement (R) has been associated with a favorable outcome in systemic ALK-negative anaplastic large cell lymphoma (ALCL). However, a recent study found that patients with DUSP22-R ALK-negative ALCL have a poorer prognosis than was reported initially. In this study, we compared the clinicopathological features and outcomes of patients with ALKnegative ALCL with DUSP22-R (n=22) versus those without DUSP22-R (DUSP22-NR; n=59). Patients with DUSP22-R ALCL were younger than those with DUSP22-NR neoplasms (P=0.049). DUSP22-R ALK-negative ALCL cases were more often positive for CD15, CD8, and less frequently expressed pSTAT3Tyr705, PD-L1, granzyme B and EMA (all P0.05), but was significantly shorter than that of the patients with ALK-positive ALCL (median overall survival 53 months vs. undefined, P=0.005). Five-year overall survival rates were 40% for patients with DUSP22-R ALCL versus 82% for patients with ALK-positive ALCL. We conclude that DUSP22-R neoplasms represent a distinctive subset of ALK-negative ALCL. However, in this cohort DUSP22-R was not associated with a better clinical outcome. Therefore, we suggest that current treatment guidelines for this subset of ALK-negative ALCL patients should not be modified at present.

Keywords

Humans, Anaplastic Lymphoma Kinase, Receptor Protein-Tyrosine Kinases, Lymphoma, Large-Cell, Anaplastic, Immunophenotyping, Prognosis, Dual-Specificity Phosphatases, Mitogen-Activated Protein Kinase Phosphatases

Comments

PMID: 36453104